FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1. Directorate Change
18 February 2025
Non-Executive Board Changes
AstraZeneca PLC announced today that Karen Knudsen will be proposed
for election as a Non-Executive Director at the Company's Annual
General Meeting on 11 April 2025.
Karen will become a member of the Science Committee and the
Sustainability Committee if elected to the Board.
Biographical details for Karen are set out below.
Current Non-Executive Directors, Deborah DiSanzo and Andreas
Rummelt will not stand for re-election this year and will retire
from the Board at the end of the AGM on 11 April 2025.
The Board has appointed Diana Layfield, Non-Executive Director as a
member of the Remuneration Committee with effect from 1 May
2025.
Michel Demaré, Chair of AstraZeneca, said "I am very pleased
Karen has accepted our invitation to join the Board. Subject
to her election by shareholders at the AGM, as a
globally-recognised cancer scientist with broad executive
experience in oncology, she will be well-positioned in respect of
the Board's work.
"Karen's deep knowledge of the US healthcare industry and medical
academic environment also makes her a great fit for
AstraZeneca. Her proposed appointment to the Board's Science
Committee and Sustainability Committee reflects the broad
contribution I believe she will make to AstraZeneca's
success.
"On behalf of the whole Board, I would like to thank Deborah
DiSanzo and Andreas Rummelt for the significant contributions they
have made to our work, as well as the insights and experience they
have brought to their roles as Board Committee members.
Deborah has been with us since 2017 and her experience at the
intersection of healthcare and technology has been very valuable as
we continue to advance our business at the forefront of science and
digital technologies. Andreas was previously a director of
Alexion and joined our Board in 2021 following AstraZeneca's
acquisition of the company, bringing important manufacturing and
supply chain experience, as well as insights into the Alexion
business at the crucial time of integration between the
organisations. Andreas has been a member of the
Sustainability Committee since its formation in 2021. We wish
them both well in their future endeavours."
Biographical details - Karen Knudsen
Karen is a globally-recognised cancer scientist and executive
leader. She has a track record of translational discoveries
in advanced prostate cancer that shaped understanding and treatment
approaches, as well as expertise in healthcare innovation,
strategic partnerships and organizational growth. Most
recently, she served as Chief Executive Officer of the American
Cancer Society (ACS) and its advocacy affiliate, ACS Cancer Action
Network, where she led the organization through a period of
transformative growth, increasing revenue and expanding research,
advocacy and patient support.
Karen previously served as Hilary Koprowski Endowed Professor and
Chair of Cancer Biology at Thomas Jefferson University and
Enterprise Director of the Sidney Kimmel Comprehensive Cancer
Center, a National Cancer Institute (NCI)-designated centre of
excellence. Karen has held various leadership roles in
oncology, including EVP of Oncology Services at Jefferson Health
and serving on the NCI Board of Scientific Advisors, as President
of the Association of American Cancer Institutes, and on the Board
of Directors of the American Association for Cancer Research.
Her contributions to oncology and healthcare leadership have been
recognized with numerous awards, including honours from the
Endocrine Society, the Prostate Cancer Foundation and the American
Society for Clinical Oncology.
Karen is Professor Emerita of Thomas Jefferson University and the
Sidney Kimmel Comprehensive Cancer Center. She is an
Independent Director of Exai Bio, serves on the board of
Research!America, and as a board adviser for ArteraAI.
Except as set out above, no disclosure obligations arise under
paragraphs (1) to (6) of UKLR 6.4.8 R of the UK Financial Conduct
Authority's Listing Rules in respect of Karen Knudsen's
appointment.
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including Cardiovascular, Renal
& Metabolism, and Respiratory & Immunology. Based
in Cambridge, UK, AstraZeneca's innovative medicines are sold
in more than 125 countries and used by millions of patients
worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
AstraZeneca
PLC
|
Date:
18 February 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|